Disease · EFO_0004285

albuminuria

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. albuminuria. Diseases, record EFO_0004285. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0004285

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: albuminuria; Open Targets
Open Targets ID: EFO_0004285; Open Targets
Other names: urinary albumin excretion; Open Targets
MeSH: D000419; MeSH
Highest stage of its drugs: Phase 3, for 5 of its 36 drugs, from ClinicalTrials.gov; Open Targets

Drugs36

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LINAGLIPTIN	CHEMBL237500	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CURCUMIN	CHEMBL140	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
RAMIPRIL	CHEMBL1168	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SEMAGLUTIDE	CHEMBL2108724	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
TELMISARTAN	CHEMBL1017	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
DAPAGLIFLOZIN	CHEMBL429910	Small molecule	Phase 2/3	ClinicalTrials.gov	6	6	6	Drugs and targets
SAXAGLIPTIN	CHEMBL2103745	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
ALISKIREN	CHEMBL1639	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
ATRASENTAN	CHEMBL9194	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
HYDROCHLOROTHIAZIDE	CHEMBL435	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 36

See all 36 drugs

Targets27

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C2	Mineralocorticoid receptor	4	Mineralocorticoid receptor antagonist; Mineralocorticoid receptor modulator	Phase 2	https://conductscience.org/library/genes/4306	Drugs and targets
AGTR1	Type-1 angiotensin II receptor	3	Type-1 angiotensin II receptor antagonist	Phase 3	https://conductscience.org/library/genes/185	Drugs and targets
GLP1R	Glucagon-like peptide 1 receptor	3	Glucagon-like peptide 1 receptor agonist	Phase 3	https://conductscience.org/library/genes/2740	Drugs and targets
EDNRA	Endothelin-1 receptor	2	Endothelin receptor ET-A antagonist	Phase 2	https://conductscience.org/library/genes/1909	Drugs and targets
ACE	Angiotensin-converting enzyme	1	Angiotensin-converting enzyme inhibitor	Phase 3	https://conductscience.org/library/genes/1636	Drugs and targets
CCR2	C-C chemokine receptor type 2	1	C-C chemokine receptor type 2 antagonist	Phase 2	https://conductscience.org/library/genes/729230	Drugs and targets
DPP4	Dipeptidyl peptidase 4	1	Dipeptidyl peptidase IV inhibitor	Phase 3	https://conductscience.org/library/genes/1803	Drugs and targets
GCGR	Glucagon receptor	1	Glucagon receptor agonist	Phase 2	https://conductscience.org/library/genes/2642	Drugs and targets
GUCY1A1	Soluble guanylate cyclase	1	Soluble guanylate cyclase activator	Phase 2	https://conductscience.org/library/genes/2982	Drugs and targets
GUCY1A2	Soluble guanylate cyclase	1	Soluble guanylate cyclase activator	Phase 2	https://conductscience.org/library/genes/2977	Drugs and targets

1 to 10 of 27

See all 27 targets

Trials33

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02547935	A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD	Phase 2/3	459	2019-06-04	Type 2 Diabetes Mellitus, CKD and Albuminuria	DAPAGLIFLOZIN, SAXAGLIPTIN	Its record names the disease	ClinicalTrials.gov
NCT01792518	MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin	Phase 3	360	2017-03-06	Diabetes Mellitus, Type 2	LINAGLIPTIN	Its record names the disease	ClinicalTrials.gov
NCT04736628	A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease	Phase 2	261	2024-09-04	Chronic Kidney Disease	AVENCIGUAT	Its record names the disease	ClinicalTrials.gov
NCT03217591	A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria	Phase 2	156	2022-09-15	Type 2 Diabetes Mellitus With Diabetic Nephropathy	PRALICIGUAT	Its record names the disease	ClinicalTrials.gov
NCT01847092	A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria	Phase 2	154	2020-05-27	Chronic Kidney Disease, Type 2 Diabetes Mellitus	TENAPANOR HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT02010242	Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria	Phase 2	136	2025-02-28	Type 2 Diabetes Mellitus With Diabetic Nephropathy	SETANAXIB	Its record names the disease	ClinicalTrials.gov
NCT03806452	SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)	Phase 2	86	2025-05-14	Sickle Cell Disease	HYDROXYUREA	Its record names the disease	ClinicalTrials.gov
NCT03118739	Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria	Phase 2	60	2020-01-10	Hyperuricemia, Albuminuria, Type 2 Diabetes	FEBUXOSTAT, VERINURAD	Its record names the disease	ClinicalTrials.gov
NCT00625820	Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria	Phase 2	17	2016-10-18	Kidney Disease, Albuminuria	SAPROPTERIN DIHYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT01732718	Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease	Phase 2	13	2019-02-05	Sickle Cell Disease, Sickle Cell Nephropathy	ATORVASTATIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 33

See all 33 trials

Comparisons in its trials17

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Linagliptin 5 mg vs Placebo: serious adverse events	17 of 182	8 of 178	360	NCT01792518	Trial comparisons
AZD1722 vs Placebo: deaths from any cause	0 of 77	0 of 77	154	NCT01847092	Trial comparisons
AZD1722 vs Placebo: serious adverse events	3 of 77	2 of 77	154	NCT01847092	Trial comparisons
GKT137831 vs Placebo: deaths from any cause	0 of 68	0 of 68	136	NCT02010242	Trial comparisons
GKT137831 vs Placebo: serious adverse events	3 of 68	5 of 68	136	NCT02010242	Trial comparisons
Hydroxycarbamide vs Placebo: deaths from any cause	0 of 46	2 of 40	86	NCT03806452	Trial comparisons
Hydroxycarbamide vs Placebo: serious adverse events	5 of 46	7 of 40	86	NCT03806452	Trial comparisons
Hydroxycarbamide vs Placebo: Proportion of Patients With a Shift From Microalbuminuria to Macroalbuminuria	3 of 43	3 of 38	81	NCT03806452	Trial comparisons
Hydroxycarbamide vs Placebo: Proportion of Patients With a Shift From Macroalbuminuria to Microalbuminuria	1 of 43	2 of 38	81	NCT03806452	Trial comparisons
Hydroxycarbamide vs Placebo: Number of Patients Achieving at Least a 30% Decrease in ACR Baseline Value	18 of 43	15 of 38	81	NCT03806452	Trial comparisons

1 to 10 of 17

See all 17 comparisons in its trials

Papers from its trials33

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31284526	RESULT	1	PubMed
29310645	RESULT	1	PubMed
27320846	RESULT	1	PubMed
26153128	RESULT	1	PubMed
24722445	RESULT	1	PubMed
17488800	RESULT	1	PubMed
42778148	DERIVED	1	PubMed
42752537	DERIVED	1	PubMed
42308057	DERIVED	1	PubMed
41805697	DERIVED	3	PubMed

1 to 10 of 33

See all 33 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0004285

GET https://conductscience.org/api/diseases/v1/EFO_0004285/drugs?page=2

API reference For AI assistants